Supinoxin

Supinoxin (RX-5902) is an orally active inhibitor of phosphorylated-p68 RNA helicase (P-p68) and a potent first-in-class anti-cancer agent. Supinoxin interacts with Y593 phosphorylated-p68 and attenuates the nuclear shuttling of β-catenin. Supinoxin induces cell apoptosis and inhibits growth of TNBC cancer cell lines with IC50s ranging from 10 nM to 20 nM[1][2].

Product Specifications

CAS Number

[888478-45-3]

Product Name Alternative

RX-5902

UNSPSC

12352005

Target

Apoptosis; DNA/RNA Synthesis

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/supinoxin.html

Purity

99.67

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(N1CCN(C2=CC(OC)=CC(OC)=C2)CC1)NC3=NC4=CC(F)=CC=C4N=C3OC

Molecular Formula

C22H24FN5O4

Molecular Weight

441.46

References & Citations

[1]Kost GC, et al. A Novel Anti-Cancer Agent, 1- (3,5-Dimethoxyphenyl) -4-[ (6-Fluoro-2-Methoxyquinoxalin-3-yl) Aminocarbonyl] Piperazine (RX-5902), Interferes With β-Catenin Function Through Y593 Phospho-p68 RNA Helicase.J Cell Biochem. 2015 Aug;116 (8) :1595-601.|[2]Capasso A, et al. First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits β-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer.Nov;18 (11) :1916-1925.